| 34.95 1.28 (3.8%) | 04-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 43.79  |
1-year : | 51.15 |
| Resists | First : | 37.5 |
Second : | 43.79 |
| Pivot price | 33.16 |
|||
| Supports | First : | 32.78 |
Second : | 29.87 |
| MAs | MA(5) : | 34.2 |
MA(20) : | 33.68  |
| MA(100) : | 33.63 |
MA(250) : | 31.25 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 74.1 |
D(3) : | 66 |
| RSI | RSI(14): 56.2 |
|||
| 52-week | High : | 43.15 | Low : | 20.4 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ VKTX ] has closed below upper band by 13.2%. Bollinger Bands are 24.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 35.07 - 35.28 | 35.28 - 35.48 |
| Low: | 32.77 - 33.01 | 33.01 - 33.24 |
| Close: | 34.57 - 34.93 | 34.93 - 35.29 |
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Wed, 08 Apr 2026
VKTX stock rises after-hours: CNBC flags Viking as likely buyout target this year as big pharma hunts next GLP-1 winner - MSN
Mon, 06 Apr 2026
Viking Therapeutics (VKTX) Is Up 7.0% After Completing Enrollment In Key VANQUISH-2 Obesity Trial - Sahm
Mon, 06 Apr 2026
Viking Therapeutics, Inc. (VKTX) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Mon, 30 Mar 2026
Viking Therapeutics (VKTX) Stock Has Failed To Impress Since Jim Cramer Expressed Caution - Yahoo Finance
Sat, 28 Mar 2026
A Look At Viking Therapeutics (VKTX) Valuation As VK2735 Phase 3 Enrollment Reaches Completion - Yahoo Finance
Thu, 26 Mar 2026
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 116 (M) |
| Shares Float | 113 (M) |
| Held by Insiders | 2.1 (%) |
| Held by Institutions | 63.1 (%) |
| Shares Short | 24,300 (K) |
| Shares Short P.Month | 26,160 (K) |
| EPS | -3.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.57 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -30.3 % |
| Return on Equity (ttm) | -47.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -279 (M) |
| Levered Free Cash Flow | -160 (M) |
| PE Ratio | -10.96 |
| PEG Ratio | 0 |
| Price to Book value | 6.27 |
| Price to Sales | 0 |
| Price to Cash Flow | -14.5 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|